Industry News
Algae Engineered By Biologists To Make Complex Anti-Cancer 'Designer' Drug
Dec 12, 2012
Biologists at UC San Diego have succeeded in genetically engineering algae to produce a complex and expensive human therapeutic drug used to treat cancer... Read More
Resistance Must Be Broken In The Fight Against Incurable Metastatic Breast Cancer
Dec 12, 2012
One of the most frustrating truths about cancer is that even when a treatment works, it often doesn't work for long because cancer cells find ways to resist. However, researchers reporting studies done in mice in the December 11, 2012, issue of Cancer Cell, a Cell Press publication, may have a way to stay one step ahead in the case of aggressive metastatic breast cancer... Read More
Apixaban Reduces Risk Of Recurrent Venous Thromboembolism
Dec 12, 2012
A recent study finds that Eliquis (apixaban), an oral factor Xa inhibitor drug, is very effective at reducing the risk of recurrent venous thromboembolism. The drug being developed by Pfizer and Bristol-Myers Squibb is an anticoagulant; it works by preventing the formation of blood clots in veins by inhibiting an enzyme in the coagulation cascade... Read More
The Significance Of Antibody Orientation
Dec 12, 2012
The orientation of antibody binding to bacteria can mean life or death to the bug, according to a study published in The Journal of Experimental Medicine. These findings may help explain why these bacteria cause millions of localized infections, but more serious, systemic blood infections are rare... Read More
Promising New Stem Cell Research, Transplant Strategies
Dec 12, 2012
Studies of stem cell biology and transplant approaches presented at the 54th Annual Meeting of the American Society of Hematology (ASH) illustrate how the use of advanced modeling techniques is optimizing stem cells to treat patients with blood disorders, as well as the potential of enhanced treatment strategies to improve the success rate of hematopoietic stem cell (HSC) tran... Read More
Addition of Everolimus to Exemestane Provides Sustained Edge in Women with Advanced Breast Cancer
Dec 11, 2012
SAN ANTONIO - The progression-free survival (PFS) benefit seen with everolimus plus exemestane over exemestane alone at 7.5 months and 12.5 months in women with advanced breast cancer is maintained at 18- month follow-up, investigators announced at the San Antonio Breast Cancer Symposium (SABCS)... Read More
Addition Of Everolimus To Exemestine Provides Sustained Survival Edge In Women With Advanced Breast Cancer
Dec 11, 2012
SAN ANTONIO - The survival benefit seen with everolimus plus exemestane over exemestane alone at 7.5 months and 12.5 months in women with advanced breast cancer is maintained at 18- month follow-up, investigators announced at the San Antonio Breast Cancer Symposium (SABCS)... Read More
Better Prostate Cancer Diagnosis - Image-Guided Biopsy
Dec 11, 2012
Magnetic resonance ultrasound fusion targeted biopsy is a better way to accurately diagnose prostate cancer, scientists from the University of California, Los Angeles, have found. Prostate cancer is the sixth leading male cancer killer, and the most common cancer among American men. It develops very slowly over time and symptoms don't usually show until it has reached an advanced stage... Read More
Prostate Cancer Now Detectable By Targeted Biopsy, Potentially Ending 25-Year Era Of Blind Biopsy
Dec 11, 2012
Ground-breaking research by a UCLA team of physicians and engineers demonstrates that prostate cancer can be diagnosed using image-guided targeted biopsy... Read More
More Than A Third Of High-Risk Leukemia Patients Respond To An Experimental New Drug
Dec 11, 2012
A new drug for patients with acute myeloid leukemia (AML) marked by a specific type of genetic mutation has shown surprising promise in a Phase II clinical trial... Read More
Previous Page Next Page